This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-19 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Macarena Hernández-Jiménez, Ph.D.
Chief Scientific Officer at AptaTargets S.L.


PhD in Biomedicine, MSc in Neuropsychology and Expert in Pharmacovigilance, with more than 15 years of experience in neurosciences and pharmacology in cerebrovascular diseases, in addition to 6 years of experience in the Stroke Spanish Investigation Consortium (INVICTUS).

Ms. Hernández-Jiménez has worked at the Ramón y Cajal Hospital (Madrid, Spain) and collaborated with 12 hospitals in the investigation of large translational preclinical studies in stroke. PhD and postdoctoral positions in topics related to cerebral hypoxia-ischemia in the hospital setting (Ramón y Cajal Hospital and La Paz Hospital) and in cerebral ischemia and pharmacology at the Complutense University (UCM). Currently, Scientific Director of aptaTargets and Associated Professor at UCM, focused on preclinical studies, nonclinical regulatory development, and clinical trials required to develop new aptameric therapies for the treatment of different diseases.

Agenda Sessions

  • Clinical Development of ApTOLL, An Aptamer for the Treatment of Acute Ischemic Stroke